the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
December 11, 2023 – In June of 2021, the American Food and Drug Administration (FDA) approved the drug semaglutide for chronic weight management under the brand name Wegovy, ushering in a new era of obesity treatment. Since then, demand for …
Semaglutide Popularity: Serious Rare Adverse Effects Are Emerging Read more »
May 17, 2017 – Following up on an earlier Drug Safety Communication from May 2016 and based on new data from two large clinical trials, the American Food & Drug Administration (FDA) has concluded that the type 2 diabetes medicines …
Risk of leg and foot amputations under Canagliflozin (Invokana, Invokamet) Read more »
Lønnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF JAMA Dermatol 2016 Apr; PMID: 27120802 Abstract Importance: Psoriasis has been shown to be associated with overweight and type 2 diabetes mellitus. The genetic association is unclear. Objective: …
Association of Psoriasis With the Risk for Type 2 Diabetes Mellitus and Obesity Read more »
September 18, 2014 – We learn today from the U.S. Food and Drug Administration (FDA) of the approval of Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with …
August 1, 2014 – The U.S. Food and Drug Administration today approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes. Type 2 diabetes affects approximately 26 million people …
FDA approves Empagliflozin [Jardiance], a SGLT2 inhibitor, to treat type 2 diabetes Read more »